These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39106643)

  • 1. Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials.
    Lynch C; Korpics MC; Katipally RR; Bestvina CM; Pitroda SP; Patel JD; Luke JJ; Chmura SJ; Juloori A
    Eur J Cancer; 2024 Sep; 209():114264. PubMed ID: 39106643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials.
    Lynch C; Korpics MC; Katipally RR; Wu T; Bestvina CM; Pitroda S; Chmura SJ; Juloori A
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1519-1530. PubMed ID: 38199382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
    Foster CC; Fleming GF; Karrison TG; Liao CY; Desai AV; Moroney JW; Ratain MJ; Nanda R; Polite BN; Hahn OM; O'Donnell PH; Vokes EE; Kindler HL; Hseu R; Janisch LA; Dai J; Hoffman MD; Weichselbaum RR; Pitroda SP; Chmura SJ; Luke JJ
    Clin Cancer Res; 2021 Oct; 27(20):5510-5518. PubMed ID: 34168049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
    Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
    J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas.
    Mahase SS; Roytman M; Roth O'Brien D; Ivanidze J; Schwartz TH; Pannullo SC; Ramakrishna R; Magge RS; Williams N; Fine HA; Chiang GC; Knisely JPS
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1788. PubMed ID: 36750401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
    Tian S; Switchenko JM; Buchwald ZS; Patel PR; Shelton JW; Kahn SE; Pillai RN; Steuer CE; Owonikoko TK; Behera M; Curran WJ; Higgins KA
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):304-313. PubMed ID: 31982496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
    Mei T; Wang T; Deng Q; Gong Y
    Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
    Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC
    Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
    Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
    Bestvina CM; Pointer KB; Karrison T; Al-Hallaq H; Hoffman PC; Jelinek MJ; Juloori A; Melotek JM; Murgu S; Partouche J; Vokes EE; Weichselbaum RR; Pitroda SP; Patel JD; Chmura SJ
    J Thorac Oncol; 2022 Jan; 17(1):130-140. PubMed ID: 34500113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study.
    Markussen A; Johansen JS; Larsen FO; Theile S; Hasselby JP; Willemoe GL; Lorentzen T; Madsen K; Høgdall E; Poulsen TS; Wilken EE; Geertsen P; Behrens CP; Svane IM; Nielsen D; Chen IM
    Clin Cancer Res; 2024 Aug; 30(16):3428-3437. PubMed ID: 38874506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy.
    Guan H; Zhou Z; Hou X; Zhang F; Zhao J; Hu K
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):35-50. PubMed ID: 35538049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
    de Ruiter BM; van Hattum JW; Lipman D; de Reijke TM; van Moorselaar RJA; van Gennep EJ; Maartje Piet AH; Donker M; van der Hulle T; Voortman J; Oddens JR; Hulshof MCCM; Bins AD
    Eur Urol; 2022 Nov; 82(5):518-526. PubMed ID: 35933242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy.
    Helis CA; Hughes RT; Glenn CW; Lanier CM; Masters AH; Dohm A; Ahmed T; Ruiz J; Triozzi P; Gondal H; Cramer CK; Tatter SB; Laxton AW; Xing F; Lo HW; Su J; Watabe K; Wang G; Whitlow CT; Chan MD
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):295-303. PubMed ID: 32615262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.